Search U.S. Product Recalls Database

Showing 121–140 of 505 results

Sort:

Succinylcholine Chloride Injection (Dr. Reddy's) – Stability Issue (2025)

Out-of-Specification (OOS) result during the 6-month stability testing; decreased preservative concentration.

FDASep 26, 2025Nationwide• Dr. Reddy's Laboratories, Inc.

RELIEVE Numbing Cream - poisoning risk (2025)

This recall involves "RELIEVE" numbing cream. The cream comes in a short wide-mouthed white container. A label is located on the front with black lettering and "RELIEVE" in large type and the company's logo and "Mad Rabbit", "Numbing Cream" and "Menthol" in smaller type.

Very High

CPSCSep 25, 2025Nationwide

Stay Informed

Search Product Recalls

Succinylcholine Chloride Injection (Dr. Reddy's) – Stability Issue (2025)

RELIEVE Numbing Cream - poisoning risk (2025)

Entecavir Tablets 0.5mg (Zydus) – Impurity Specifications (2025)

Entecavir Tablets 1mg (Zydus) – Impurity Specifications (2025)

Fentanyl/Ropivacaine Solution (Park Avenue) – CGMP Deviation (2025)

Atorvastatin Tablets 40mg (Ascend) – Dissolution Failure (2025)

Atorvastatin Tablets 80mg (Ascend) – Dissolution Failure (2025)

Atorvastatin Tablets 20mg (Ascend) – Dissolution Failure (2025)

Atorvastatin Tablets 10mg (Ascend) – Dissolution Failure (2025)

Phenylephrine HCI (Park Avenue) – CGMP Deviation (2025)

Azelaic Acid Gel (Glenmark) – Texture Complaint (2025)

Oxytocin IV Solution (IntegraDose) – No Active Ingredient (2025)

Levothyroxine Tablets (Accord) – Subpotent Medication (2025)

Bupropion XL Tablets (Graviti) – Tablet Specification Failure (2025)

Carbamazepine Tablets (Amerisource) – Dissolution Issue (2025)

Baby Bedtime Drops (M.O.M Enterprises) – Yeast Contamination (2025)

Cetirizine Hydrochloride Tablets 500ct (JB Chemicals) – incorrect tablet imprint (2025)

ChlorproMAZINE Hydrochloride Tablets (Major Pharmaceuticals) – N-Nitroso impurity (2025)

Cetirizine Hydrochloride Tablets (JB Chemicals) – incorrect tablet imprint (2025)

Bariatric Fusion Iron Multivitamins (VitaQuest) – Serious Injury Risk (2025)